Policy | August 11, 2021
NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Subscribe To Our Newsletter & Stay Updated
